Clene's CNM-Au8 Shows Promise in Parkinson's Disease Preclinical Study
TL;DR
Clene's CNM-Au8 offers a first-in-class therapeutic advantage by improving mitochondrial function and reducing inflammation in Parkinson's disease neurons.
CNM-Au8 works by correcting metabolic imbalances, normalizing gene expression, and improving mitochondrial health with no observed toxicity in preclinical models.
This neuroprotective therapy could significantly improve quality of life for Parkinson's patients by addressing both familial and sporadic forms of the disease.
Gold nanocrystals from Clene restored cellular metabolism in Parkinson's neurons through a novel mechanism targeting mitochondrial function.
Found this article helpful?
Share it with your network and spread the knowledge!
Clene Inc. (NASDAQ: CLNN) has presented new preclinical data showing that its investigational drug CNM-Au8 improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a Parkinson's disease model. The findings, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting, indicate that CNM-Au8 corrected metabolic imbalances and normalized dysregulated gene expression in dopaminergic neurons affected by Parkinson's disease.
The study, conducted in collaboration with the Salk Institute and supported by Michael J. Fox Foundation funding, demonstrated that CNM-Au8 exhibited a favorable safety profile with no observed toxicity in Parkinson's disease neurons. This research underscores the drug's potential as a neuroprotective therapy that could benefit both familial and sporadic forms of Parkinson's disease, addressing a significant unmet medical need in neurodegenerative disease treatment.
Clene Inc., through its subsidiary Clene Nanomedicine Inc., is developing CNM-Au8 as a first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The company's focus on improving mitochondrial health and protecting neuronal function represents a novel approach to treating neurodegenerative diseases including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. For more information about the company's research, visit https://www.clene.com.
The preclinical data suggests that CNM-Au8's mechanism of action could provide neuroprotective benefits by addressing fundamental cellular dysfunctions in Parkinson's disease. The ability to improve mitochondrial function and reduce inflammation could potentially slow disease progression and preserve neuronal function, which is crucial for maintaining motor control and cognitive abilities in Parkinson's patients. The full press release detailing these findings is available at https://ibn.fm/B9Coc.
This development is significant for the approximately 10 million people worldwide living with Parkinson's disease, as current treatments primarily address symptoms rather than underlying disease progression. The neuroprotective approach demonstrated by CNM-Au8 could represent a paradigm shift in Parkinson's treatment strategies, potentially offering long-term benefits for patients facing this progressive neurodegenerative disorder.
Curated from InvestorBrandNetwork (IBN)
